Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Osimertinib,OsiStudy001,2022,USA,MDV,350,68,52,48,26.5,35,85,5,15,30,40,15,45,30,15,10,20,35,45,18,8,5,12,7,10,25,30,Cisplatin + Pemetrexed,Carboplatin + Paclitaxel,Pemetrexed,Vinorelbine,2,3,1,20,40,50,15,55,30,60,2
Osimertinib,OsiStudy002,2023,Japan,Claim Database,420,72,48,52,24.8,40,78,3,12,28,42,18,48,28,14,10,18,32,50,20,10,6,14,8,8,22,28,Cisplatin + Docetaxel,Carboplatin + Pemetrexed,Docetaxel,Gemcitabine,1,2,0.5,22,42,52,20,60,20,70,1.5
Osimertinib,OsiStudy003,2023,UK,MDV,280,65,55,45,27.1,30,90,4,18,32,35,15,50,25,15,10,22,38,40,15,7,4,10,6,12,28,32,Carboplatin + Paclitaxel,Cisplatin + Etoposide,Paclitaxel,Docetaxel,3,4,2,18,38,48,10,50,40,65,2.5
